New Targeted Drug Nearly Doubles Survival Time For Pancreatic Cancer Patients In Major Trial
When patients sit in my office to discuss a metastatic pancreatic cancer diagnosis, their first question is almost always about their true life expectancy. For a long time, the survival statistics have been difficult to discuss. Our primary tool has been intravenous chemotherapy. It offers limited success and brings heavy toxicity. That is why the…
